3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Other solid neoplasm
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Conditions
Sarcoma, Ewing
2
Sarcoma
2
Rhabdomyosarcoma
2
Osteosarcoma
2
Wilms Tumor
1
Sarcoma, Myeloid
1
Sarcoma, Clear Cell
1
Rhabdoid Tumor
1
Retinoblastoma
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Lymphoma
1
Leukemia, Myeloid, Acute
1
Leukemia, Biphenotypic, Acute
1
Hepatoblastoma
1
Desmoplastic Small Round Cell Tumor
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Bone Neoplasms
1
Interventions
tazemetostat
6
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Cyclophosphamide
6
Specimen Handling
5
Etoposide
5
Carboplatin
5
etoposide phosphate
4
Temozolomide
4
Nuclear Medicine Department, Hospital
4
Granulocyte Colony-Stimulating Factor
4
palbociclib
3
Topotecan
3
Thiotepa
3
Sirolimus
3
Mesna
3
Melphalan
3
Ifosfamide
3
Filgrastim
3
Busulfan
3
Biopsy
3
ulixertinib
2
tipifarnib
2
selpercatinib
2
omburtamab I-131
2
olaparib
2
larotrectinib
2
ivosidenib
2
fludarabine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Rhabdoid Tumor
×
pegylated granulocyte colony-stimulating factor
×
Sarcoma
×
Clear all
NCT02390843
2020-04-03
AflacST1402
Emory University
Phase 1
Completed
13 enrolled